TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8775698
Drug: Postoperative physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative physical therapy (Control)
Study: 6150000
Drug: Guanfacine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (2 mg)
Study: 6150000
Drug: RX 781094
Approvals — FDA: no, EMA: no, PMDA: no
Description: RX 781094 (0.3 mg/kg)
Study: 24532078
Drug: Tadalafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (20 mg/die for 2 days)
Study: 21075465
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy for heart failure
Study: 20397457
Drug: Body acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body acupuncture plus auricular‐plaster therapy
Study: 20397457
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Baihui (GV 20)‐through‐Sishencong (EX‐HN1) puncture, auricular‐plaster therapy and moxibustion on the back‐shu points not used)
Study: 17666604
Drug: Tinidazole 1
Normalized name: tinidazole 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 1 g once daily for 5 days
Study: 17666604
Drug: Tinidazole 2
Normalized name: tinidazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 2 g once daily for 2 days
Study: 12244386
Drug: 0.1 mg/Kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/Kg chlorpromazine intravenously
Study: 12244386
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 ml of saline intravenous injections)
Study: 9988395
Drug: Oral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen (E2 valerate, 2 mg/d) plus medroxyprogesterone acetate (5 mg/d) administered during weeks 3, 4, 7, and 8 for 8 weeks
Study: 9988395
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen (50‐microg or 100‐microg E2 patch)
Study: 7564363
Drug: Remikiren (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remikiren (single oral administration)
Study: 2197005
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine 0.5 mg.kg‐1 in 7.5% glucose (n = 20)
Study: 2197005
Drug: 5% meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% meperidine 0.5 mg.kg‐1 (n = 22)
Study: 19074663
Drug: Continuous highly
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous highly active antiretroviral therapy (HAART) for 24 months (arm A)
Study: 19074663
Drug: Intermittent highly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent highly active antiretroviral therapy (HAART) for 24 months (arm B)
Study: 16705107
Drug: Policosanol 20
Normalized name: POLICOSANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 20 mg/d
Study: 16705107
Drug: Policosanol 40
Normalized name: POLICOSANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 40 mg/d
Study: 16705107
Drug: Policosanol 80
Normalized name: POLICOSANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 80 mg/d
Study: 7545448
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (5 g total)
Study: 7545448
Drug: Control (neither
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (neither drug nor placebo)
Study: 3898418
Drug: Pethidine 100
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 100 mg
Study: 7000136
Drug: Oral psoralen
Normalized name: Psoralen
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral psoralen and long-wave ultraviolet light (treated side)
Study: 7000136
Drug: Topical psoralen
Normalized name: Psoralen
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical psoralen and long-wave ultraviolet light (previously control side)
Study: 29361199
Drug: Mavrilimumab 100
Normalized name: Mavrilimumab
DrugBank: Mavrilimumab (DB12534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavrilimumab 100 mg every other week plus methotrexate
Study: 29361199
Drug: Mavrilimumab (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavrilimumab (30, 100, or 150 mg) or placebo every other week plus methotrexate
Study: 26297124
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg for 1 month, then 10 mg for the rest of the months, once daily)
Study: 21050887
Drug: DMB‐SR floating
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMB‐SR floating tablets (HPMC K4M 25 mg, sodium bicarbonate 20 mg, hexadecanol 18 mg)
Study: 21050887
Drug: Conventional DMB‐SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional DMB‐SR tablets
Study: 16315025
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogen + 2.5 mg medroxyprogesterone acetate (CEE/MPA)
Study: 16315025
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 17beta estradiol + 0.5 mg norethindrone acetate (E2/NETA)
Study: 14570797
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of propofol
Study: 14570797
Drug: Bolus followed
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus followed by infusion of propofol
Study: 10195538
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine 2 mg/mL with fentanyl 4 microg/mL (Group R4F)
Study: 10195538
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine 2 mg/mL alone (Group R)
Study: 10195538
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine 2 mg/mL with fentanyl 1 microg/mL (Group R1F)
Study: 10195538
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine 2 mg/mL with fentanyl 2 microg/mL (Group R2F)
Study: 10195538
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine 2 mg/mL with fentanyl (all doses)
Study: 7756100
Drug: Physostigmine transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine transdermal system (PTS)
Study: 27959941
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: 231299
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg cephradine every 6 h for 7 days
Study: 231299
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg pivmecillinam every 6 h for 7 days
Study: 231299
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg cephradine
Study: 231299
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg pivmecillinam
Study: 30040135
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg, single oral dose)
Study: 27618796
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg intravenous amisulpride
Study: 22113087
Drug: Org 25935
Normalized name: ORG-25935
DrugBank: ORG-25935 (DB12220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 25935 (glycine transporter-1 inhibitor)
Study: 19189246
Drug: S. chrysotrichum
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. chrysotrichum herbal medicinal product (Sc-hmp), standardized in 1.89 mg of SC-2, administered as vaginal suppositories daily for 7 nights
Study: 19189246
Drug: Ketoconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (400 mg), administered as vaginal suppositories daily for 7 nights
Study: 11991625
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g lactulose meal
Study: 11991625
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g sucrose meal followed by colonic infusion of 40 g lactulose
Study: 9704778
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid and vitamin B6 supplementation with aspirin
Study: 8556974
Drug: Mazindol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mazindol (2 mg QD)
Study: 31714583
Drug: Glucagon (300/150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (300/150 μg)
Study: 29596222
Drug: Micafungin (MCA)
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micafungin (MCA) 10 mg/kg/d for ≥21 days
Study: 29596222
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B Deoxycholate (AmB-D) 1 mg/kg/d for ≥21 days
Study: 28723799
Drug: TACE with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE with GSPs plus lobaplatin chemotherapy
Study: 25028065
Drug: Encenicline (alpha-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encenicline (alpha-7 nicotine agonist)
Study: 23319176
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of HZ vaccine (0.65 mL)
Study: 23319176
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of HZ vaccine at 0 and 1 month
Study: 23319176
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of HZ vaccine at 0 and 3 months
Study: 23319176
Drug: Two-dose vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose vaccination (both schedules)
Study: 18419402
Drug: HZ vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HZ vaccine
Study: 22018642
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg for 6 months
Study: 15571954
Drug: Intraventricular chemotherapy
Normalized name: cerliponase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraventricular chemotherapy (IT)
Study: 15571954
Drug: Non-intrathecal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-intrathecal treatment (non-IT)
Study: 8106654
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 to 40 mg)
Study: 8106654
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 to 60 mg)
Study: 2446057
Drug: Ketanserin (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (20-40 mg b.i.d.)
Study: 2446057
Drug: Methyldopa (250-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (250-500 mg b.i.d.)
Study: 18520294
Drug: Sorafenib (monotherapy)
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib (monotherapy)
Study: 18520294
Drug: Sorafenib (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (in combination with chemotherapy)
Study: 18520294
Drug: Sorafenib (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (in combination with epidermal growth factor receptor inhibitors)
Study: 18520294
Drug: Bevacizumab (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (in combination with cytotoxic chemotherapy)
Study: 15893182
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg and fenofibrate 200 mg
Study: 16160590
Drug: Fenofibrate 200
Normalized name: fenofibrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 200 mg
Study: 12887139
Drug: Phentermine 37.5
Normalized name: PHENTERMINE 37.5MG TAB,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine 37.5 mg
Study: 26773325
Drug: lexaptepid pegol
Normalized name: Lexaptepid pegol
DrugBank: Lexaptepid pegol (DB12578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lexaptepid pegol (1.2 mg·kg(‐1) i.v.)
Study: 26773325
Drug: lexaptepid pegol
Normalized name: Lexaptepid pegol
DrugBank: Lexaptepid pegol (DB12578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lexaptepid pegol (doses from 0.3 to 4.8 mg·kg(‐1))
Study: 26773325
Drug: lexaptepid pegol
Normalized name: Lexaptepid pegol
DrugBank: Lexaptepid pegol (DB12578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lexaptepid pegol (≥2.4 mg·kg(‐1))
Study: 26773325
Drug: lexaptepid pegol
Normalized name: Lexaptepid pegol
DrugBank: Lexaptepid pegol (DB12578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lexaptepid pegol (s.c. administration)
Study: 21997675
Drug: Ingested water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingested water (300 ml labeled with D₂O; osmolality <20 mOsm kg(‐1))
Study: 15462687
Drug: NSAIDs (ibuprofen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (ibuprofen, diclofenac, nabumetone, or naproxen, combined, N = 7046)
Study: 15884512
Drug: Subconjunctival MMC
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subconjunctival MMC (0.2 mg/ml for 3 minutes)
Study: 15884512
Drug: Intrascleral MMC
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrascleral MMC (0.2 mg/ml for 3 minutes)
Study: 9598903
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose methotrexate (10 mg/m2 body surface area/wk)
Study: 9598903
Drug: D-penicillamine, hydroxychloroquine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine, hydroxychloroquine, auranofin, very low dose methotrexate
Study: 8159444
Drug: Treatment: full
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment: full occlusal splint worn 24 h/day
Study: 23681967
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human ACE2 (rhACE2) 100-1200 μg/kg single dose
Study: 23681967
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human ACE2 (rhACE2) 400 μg/kg repeated dosing for 3 or 6 days
Study: 19685109
Drug: Priming with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Priming with vecuronium (0.02 mg.kg(‐1))
Study: 19685109
Drug: Priming with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Priming with rocuronium (0.06 mg.kg(‐1))
Study: 15271118
Drug: Nutrition supplements
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition supplements provided between breakfast and lunch for 21 consecutive days
Study: 9685273
Drug: Intensive cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive cognitive behaviour therapy
Study: 2546659
Drug: Ketotifen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (1 mg b.i.d., orally)
Study: 31300907
Drug: Laparoscopic pancreaticoduodenectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic pancreaticoduodenectomy (L-PD)
Study: 23659666
Drug: Erythropoietin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (1000 IU/kg for three daily doses)
Study: 23659666
Drug: Phenobarbital (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (40 mg/kg single dose)
Study: 23659666
Drug: Control (supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (supportive treatment)
Study: 21157296
Drug: K103N viral
Approvals — FDA: no, EMA: no, PMDA: no
Description: K103N viral load at least 2000 copies/ml
Study: 15069730
Drug: Hemoperfusion adsorption
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoperfusion adsorption therapy
Study: 3884114
Drug: Plasma exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange therapy
Study: 15069730
Drug: Plasma exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange plus hemoperfusion adsorption therapy
Study: 11834182
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with Cupressus arizonica
Study: 8290193
Drug: Intramuscular ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ketorolac (60 mg)
Study: 7618770
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (800 mg)
Study: 9492131
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (ketorolac and ibuprofen)
Study: 2577273
Drug: Maintenance drug
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance drug treatment
Study: 2577273
Drug: Drug withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug withdrawal
Study: 31707181
Drug: Modified gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified gemcitabine and oxaliplatin (mGemOx) - gemcitabine 900 mg/m2, oxaliplatin 80 mg/m2, maximum 6 cycles
Study: 31707181
Drug: Gemcitabine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine + cisplatin (CisGem) - gemcitabine 1000 mg/m2, cisplatin 25 mg/m2, maximum 8 cycles
Study: 28893900
Drug: Labetalol (200‐1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (200‐1800 mg/d)
Study: 28893900
Drug: Nifedipine (20‐80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20‐80 mg/d)
Study: 19689824
Drug: Kneipp hydrotherapy
Normalized name: CAMPHOR (SYNTHETIC) 0.001 mg in 1 mL / SODIUM BICARBONATE 0.05 mg in 1 mL TOPICAL LOTION [ProloGel Neurotherapy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kneipp hydrotherapy (daily, with alternate cold and warm thigh affusions)
Study: 19689824
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of physiotherapy and hydrotherapy (joint-specific physiotherapy three times a week and daily alternate cold and warm thigh affusions)
Study: 24249722
Drug: ACEI-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI-based therapy
Study: 10602973
Drug: iopromide 240
Normalized name: IOPROMIDE 240mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopromide 240 mgI/ml
Study: 7731768
Drug: iohexol 240
Normalized name: iohexol 240 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol 240 mgI/ml
Study: 8529760
Drug: Insulin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.3 IU/Kg BW at 10-11 p.m.)
Study: 31821361
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg/day)
Study: 8529760
Drug: Acarbose (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (3 x 100 mg daily)
Study: 29693715
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide (5 mg for 5 days followed by 10 mg for 5 days)
Study: 27574886
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin combined with insulin (LMWH+insulin)
Study: 19406493
Drug: Enoxaparin and
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin and unfractionated heparin (no specific dosage or duration mentioned)
Study: 20375405
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1000 mg) and Vitamin E (400 IU) supplementation
Study: 9068393
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg alteplase
Study: 4009330
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration with solution A and solution B
Study: 29280064
Drug: Macitentan in
Normalized name: Product containing macitentan in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macitentan in combination with background therapy (PDE‐5i)
Study: 29280064
Drug: Background therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Background therapy only (placebo arm)
Study: 26194532
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist analogue administered at a dose interval of 3 days and/or a monthly dose of GnRHa during chemotherapy
Study: 26194532
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist analogue
Study: 25450320
Drug: Protoconized anemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protoconized anemia therapy with adjusted doses of erythropoietin, iron, and vitamin C based on Hb and ferritin levels.
Study: 25450320
Drug: Non‐intervention group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐intervention group with doses of erythropoietin and iron determined by the attending physician.
Study: 22435409
Drug: Essential oil
Normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential oil group (n = 24) using blended essential oils (lavender, clary sage, marjoram) in a 3% concentration cream, massaged daily on lower abdomen.
Study: 18344428
Drug: Pilocarpine, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine, 5 mg orally every 8 hours for 1 week after 131I therapy
Study: 10556111
Drug: Salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (50 microgram twice daily)
Study: 10556111
Drug: Fluticasone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (100 microgram twice daily)
Study: 8739023
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg Y-27152
Study: 8739023
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg Y-27152
Study: 8739023
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg Y-27152
Study: 8739023
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg Y-27152 (fasting)
Study: 8739023
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg Y-27152 (after food)
Study: 8739023
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg Y-27152
Study: 8739023
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg Y-27152 (multiple doses)
Study: 8739023
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg Y-27152 (multiple doses)
Study: 8739023
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg Y-27152 (multiple doses)